Delivery alert

There may be an issue with the delivery of your newspaper. This alert will expire at NaN. Click here for more info.

Recover password

Sandia scientists seek genetic bullet

Two Sandia National Laboratories researchers are using genetic resequencing tools to find a way to stop the COVID-19 pandemic.

Biochemist Joe Schoeniger and virologist Oscar Negrete are working on genetically engineering a deployable antiviral countermeasure for COVID-19 using CRISPR-based technology.

Oscar Negrete/Courtesy Sandia National Laboratories

“The goal is to find new ‘reloadable’ countermeasures for viral outbreaks that do not have to be re-invented every time,” Schoeniger said. “CRISPR is a technology that allows us to address specific sequences of DNA and RNA, safely editing genes or controlling gene expression, to target viruses and improve the body’s ability to resist infection.”

Once their research is complete, the antiviral will be able to be customized to respond to many different viruses, including coronavirus.

“We are developing safe CRISPR-based technologies that send temporary reprogramming codes to your body that will inhibit virus infection,” Negrete said. “We’re also developing nanoparticle delivery systems to protect the CRISPR constructs until they get to the right cells and tissues to modulate the body’s response.”

This CRISPR-based research is funded by the Biological Technologies Office in the Defense Advanced Research Projects Agency.

Joe Schoeniger/Courtesy Sandia National Laboratories

“I think this current pandemic shows that we have a vulnerability to this and that this is more than a health problem. It is a national security problem,” Schoeniger said. “Coronavirus was already on our radar. When the new strain called SARS-CoV-2 emerged and it was clear this was not a local problem in China, we started to pivot to that research pretty early. We’ve added on more institutional work since then.”

The team is conducting proof-of-concept trials now, after which other institutions involved in the research will conduct animal testing of the modified genes. Schoeniger said the work will continue even if this outbreak is controlled.

“There’s a long tail that’s going to be around for a while,” he said. “Things can happen during that tail that we can’t know. We want to help reinforce that response to not only a new outbreak of COVID-19 but outbreaks of all kinds.”

Schoeniger, M.D./Ph.D., is a biochemist at Sandia and systems biology manager. Negrete, Ph.D., is a virologist focused on emerging viruses and molecular viral-host interaction. About 1,500 people work at Sandia’s second principal laboratory in Livermore, California.

Albuquerque Journal and its reporters are committed to telling the stories of our community.

• Do you have a story about how coronavirus has affected you, your family or your business? Do you have a question you want someone to try to answer for you? What issues related to the topic would you like to see covered? Or do you have a bright spot you want to share in these troubling times?
   We want to hear from you. Please email or Contact the writer.